Ixekizumab versus FAEs and methotrexate in treatment of nail psoriasis in patients with moderate‐to‐severe psoriasis-Reference-Cited by-同舟云学术

Ixekizumab versus FAEs and methotrexate in treatment of nail psoriasis in patients with moderate‐to‐severe psoriasis

Published:2024-01-07 Issue:2 Volume:22 Page:278-281
ISSN:1610-0379
Container-title:JDDG: Journal der Deutschen Dermatologischen Gesellschaft
language:en
Short-container-title:J Deutsche Derma Gesell

Author:

Augustin Matthias¹^ORCID,Mrowietz Ulrich²,Willsmann‐Theis Dagmar³^ORCID,Gerdes Sascha²,Fotiou Konstantinos⁴,Schuster Christopher⁴⁵,Mert Can⁶,Holzkaemper Thorsten⁴,Behrens Frank⁷,Pinter Andreas⁸

Affiliation:

1. German Center for Health Services Research in Dermatology Institute for Health Services Research in Dermatology and Nursing (IVDP) University Medical Center Hamburg‐Eppendorf (UKE) Hamburg Germany

2. Department of Dermatology Psoriasis‐Center University Medical Center Schleswig‐Holstein, Kiel Campus Kiel Germany

3. Clinic and Polyclinic for Dermatology and Allergology University Hospital Bonn Bonn Germany

4. Eli Lilly and Company Indianapolis Indiana USA

5. Department of Dermatology Medical University of Vienna Vienna Austria

6. HaaPACS GmbH Schriesheim Germany

7. Center for Innovative Diagnostics and Therapy Rheumatology/Immunology (CIRI) of the University of Frankfurt Frankfurt am Main Germany

8. Department of Dermatology Venereology and Allergology University Hospital Frankfurt Frankfurt am Main Germany

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ddg.15292

Reference11 articles.

1. Nail psoriasis: a questionnaire-based survey

2. Nail psoriasis in Germany: epidemiology and burden of disease

3. Definition of treatment goals for moderate to severe psoriasis: a European consensus

4. Psoriatic arthritis for dermatologists

5. Ixekizumab and Ustekinumab Efficacy in Nail Psoriasis in Patients with Moderate-to-Severe Psoriasis: 52-Week Results from a Phase 3, Head-to-Head Study (IXORA-S)